Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Darvish Nissim	2. Date of Event Requiring Statement (MM/DD/YYYY) 3/16/2021	3. Issuer Name and Ticker or Trading Symbol Chemomab Therapeutics Ltd. [CMMB]
(Last)        (First)        (Middle) C/O CHEMOMAB THERAPEUTICS LTD.,, KIRYAT ATIDIM, BUILDING 7	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                          _____ 10% Owner _____ Officer (give title below)        _____ Other (specify below)
(Street) TEL AVIV, L3 6158002       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase American Depositary Shares	(1)	10/27/2026	American Depositary Shares (2)	10123	$0.80	D

Explanation of Responses:
(1)	The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.
(2)	Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

Remarks: Exhibit 24.1: Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Darvish Nissim C/O CHEMOMAB THERAPEUTICS LTD., KIRYAT ATIDIM, BUILDING 7 TEL AVIV, L3 6158002	X

Signatures
/s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish		3/25/2021
**Signature of Reporting Person		Date